Cargando…
GammaTile® brachytherapy in the treatment of recurrent glioblastomas
BACKGROUND: GammaTile® (GT) is a recent U.S. Food and Drug Administration (FDA) cleared brachytherapy platform. Here, we report clinical outcomes for recurrent glioblastoma patients after GT treatment following maximal safe resection. METHODS: We prospectively followed twenty-two consecutive Isocitr...
Autores principales: | Gessler, Dominic J, Neil, Elizabeth C, Shah, Rena, Levine, Joseph, Shanks, James, Wilke, Christopher, Reynolds, Margaret, Zhang, Shunqing, Özütemiz, Can, Gencturk, Mehmet, Folkertsma, Mark, Bell, W Robert, Chen, Liam, Ferreira, Clara, Dusenbery, Kathryn, Chen, Clark C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788013/ https://www.ncbi.nlm.nih.gov/pubmed/35088050 http://dx.doi.org/10.1093/noajnl/vdab185 |
Ejemplares similares
-
GammaTile® (GT) as a brachytherapy platform for rapidly growing brain metastasis
por: Dharnipragada, Rajiv, et al.
Publicado: (2023) -
Rapid Interval Recurrence of Glioblastoma Following Gross Total Resection: A Possible Indication for GammaTileⓇ Brachytherapy
por: Easwaran, Teresa P, et al.
Publicado: (2021) -
GammaTile for Gliomas: A Single-Center Case Series
por: Budnick, Hailey C, et al.
Publicado: (2021) -
Treating Recurrent Brain Metastases Using GammaTile Brachytherapy: A Case Report and Dosimetric Modeling Method
por: Arsenault, Theodore, et al.
Publicado: (2021) -
First application of GammaTile cesium-131 brachytherapy with maximal safe resection of a glioma in a patient with limited scleroderma
por: Pasli, Melisa, et al.
Publicado: (2023)